Graft-versus-tumor effect of suicide gene-modified T cells
| Patient no. . | Disease . | TK+ cells infused, 106/kg . | Peak of TK+ cells/μL (% of PBLs)* . | Outcome after TK-DLI† . | GvHD after TK-DLI† . | GvHD response after GCV treatment . | OS, wk after TK-DLI . |
|---|---|---|---|---|---|---|---|
| 1 | EBV+PTLD | 1.5 | 166 (13) | CR | Y | Y | 13‡ |
| 2 | CML | 38.6 | 115 (4.9) | PR | Y | Y | 89 |
| 3 | CML | 0.5 | 39 (3.3) | PR | N | NA | 104 |
| 4 | AML | 3.3 | NE | NE | NE | NA | NE |
| 5 | AML | 5.2 | 12 (1.9) | NR | N | NA | 12 |
| 6 | EBV+PTLD | 0.5 | NE | NE | NE | NA | NE |
| 7 | AML | 11.1 | 37.4 (3.4) | CR§ | N | NA | 85‡ |
| 8 | CMML | 20.0 | 75 (11.9) | CR | Y | Y | 556‖ |
| 9 | ALL | 1.0 | NE | NE | NE | E | NE |
| 10 | AML | 1.0 | 10 (6) | NR | NE | NA | 8 |
| 11 | AML | 110.0 | 103 (3.2) | PR | N | NA | 10 |
| 12 | AML | 24.0 | 115 (17) | NE¶ | NE | NA | 8 |
| 13 | AML | 10.0 | 8 (1.7) | NR | NE | E | 10 |
| 14 | AML | 80.0 | NE | NE | NE | E | NE |
| 15 | ALL | 100.0 | NE | NE | NE | NA | NE |
| 16 | FCL | 280.0 | 56 (4) | CR | N | NA | 471‖ |
| 17 | MM | 47.0 | 56 (1) | CR | N | NA | 166 |
| 18 | HD | 80.0 | PCR+ | NR | NE | NA | 6 |
| 19 | AML | 145.0 | NE | NE | NE | E | NE |
| 20 | MM | 300.0 | PCR+ | PR | N | NA | 76 |
| 21 | CML | 50.0 | PCR+ | CR | N | NA | 405‖ |
| 22 | HD | 110.0 | 77 (2.4) | NR | Y | NA | 15 |
| 23 | MCL | 120.0 | 120 (9.7) | PR | NE | NA | 4 |
| Patient no. . | Disease . | TK+ cells infused, 106/kg . | Peak of TK+ cells/μL (% of PBLs)* . | Outcome after TK-DLI† . | GvHD after TK-DLI† . | GvHD response after GCV treatment . | OS, wk after TK-DLI . |
|---|---|---|---|---|---|---|---|
| 1 | EBV+PTLD | 1.5 | 166 (13) | CR | Y | Y | 13‡ |
| 2 | CML | 38.6 | 115 (4.9) | PR | Y | Y | 89 |
| 3 | CML | 0.5 | 39 (3.3) | PR | N | NA | 104 |
| 4 | AML | 3.3 | NE | NE | NE | NA | NE |
| 5 | AML | 5.2 | 12 (1.9) | NR | N | NA | 12 |
| 6 | EBV+PTLD | 0.5 | NE | NE | NE | NA | NE |
| 7 | AML | 11.1 | 37.4 (3.4) | CR§ | N | NA | 85‡ |
| 8 | CMML | 20.0 | 75 (11.9) | CR | Y | Y | 556‖ |
| 9 | ALL | 1.0 | NE | NE | NE | E | NE |
| 10 | AML | 1.0 | 10 (6) | NR | NE | NA | 8 |
| 11 | AML | 110.0 | 103 (3.2) | PR | N | NA | 10 |
| 12 | AML | 24.0 | 115 (17) | NE¶ | NE | NA | 8 |
| 13 | AML | 10.0 | 8 (1.7) | NR | NE | E | 10 |
| 14 | AML | 80.0 | NE | NE | NE | E | NE |
| 15 | ALL | 100.0 | NE | NE | NE | NA | NE |
| 16 | FCL | 280.0 | 56 (4) | CR | N | NA | 471‖ |
| 17 | MM | 47.0 | 56 (1) | CR | N | NA | 166 |
| 18 | HD | 80.0 | PCR+ | NR | NE | NA | 6 |
| 19 | AML | 145.0 | NE | NE | NE | E | NE |
| 20 | MM | 300.0 | PCR+ | PR | N | NA | 76 |
| 21 | CML | 50.0 | PCR+ | CR | N | NA | 405‖ |
| 22 | HD | 110.0 | 77 (2.4) | NR | Y | NA | 15 |
| 23 | MCL | 120.0 | 120 (9.7) | PR | NE | NA | 4 |
Y indicates yes; N, no; NA, data not available; NE, not evalulable; and E, elimination of transduced cells with ganciclovir treatment, in the absence of GvHD. Additional abbreviations are explained in Table 1.
Peak of circulating TK+ cells is reported as the highest level of TK+ cells quantified by FACS for ΔLNGFR expression. In case of FACS negativity, the peak of TK+ cells was quantified by PCR for the HSV-TK transgene.
Responses after TK-DLI are evaluated according to standard criteria. GvHD was diagnosed according to Glucksberg criteria.
Death in CR.
Patient received debulking chemotherapy with ARA-C 100 mg/ms × 7 days + daunorubicine 20 mg/kg × 3 days and obtained hematologic remission.
Alive in CR.
Patient not evaluable for GvL; however, a marked antiviral response with clearance of CMV reactivation was observed.